Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Sevilla – page 54

1 637 clinical trials in Sevilla, Spain across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Sevilla at a glance
1 637
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

1 637 trials in Sevilla

Open in trial search
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:AstraZeneca AB

Acromegaly

Not yet recruiting

Short-Acting Pasireotide Test to Predict Treatment Response in Patients with Acromegaly

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pasireotide
  • Sponsor:Instituto De Investigacion En Ciencias De La Salud Germans Trias I Pujol

Adenocarcinoma pancreas

Not yet recruiting

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:(2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE
  • Sponsor:Revolution Medicines Inc.

Plasma cell myeloma

Not yet recruiting

Phase 3 study comparing linvoseltamab and daratumumab in high‑risk smoldering multiple myeloma patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Immune thrombocytopenia

Not yet recruiting

Phase 3 Study of Romiplostim Combined with Prednisolone versus Prednisolone Alone in Adults with Previously Untreated Primary Immune Thrombocytopenia (ITP)

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Amgen Inc.

Adrenogenital syndrome

Not yet recruiting

Study of Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia to Reduce Androgen Levels

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Crinecerfont
  • Sponsor:Neurocrine Biosciences Inc.

Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis: Phase 2/3 Open‑Label and Randomized Placebo‑Controlled Study

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Apellis Pharmaceuticals Inc.

Neoplasm

Not yet recruiting

Study of IDE849, IDE‑161 and durvalumab evaluating safety and efficacy in patients with DLL3‑positive tumors including small cell lung cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Ideaya Biosciences Inc.

Psychotic disorder+2

Not yet recruiting

A Randomized Controlled Trial of Cannabidiol vs Placebo Augmentation in Patients with First Episode Psychosis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Cannabidiol
  • Sponsor:University Of Oxford

Pulmonary hypertension

Not yet recruiting

Long‑Term Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

Parkinson's disease

Not yet recruiting

Efficacy of intravenous prasinezumab versus placebo in Parkinson's disease patients with severe GBA mutation: a 104‑week randomized double‑blind study

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Prasinezumab
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Cystic fibrosis

Not yet recruiting

Safety and Efficacy of VX-828, Deutivacaftor, and Tezacaftor in Adults with Cystic Fibrosis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Vertex Pharmaceuticals Inc.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Sevilla

What the registry says about research in the country

01 Metabolic and Endocrine Disorders

Innovative research focusing on Type 1 Diabetes management and weight-related conditions, evaluating new therapeutic approaches for glycemic control and metabolic health.

  • Diabetes Management
  • Obesity Treatment
  • Metabolic Disorders

Studies aim to improve treatment outcomes for patients with complex metabolic conditions.

02 Neurological Conditions

Advanced clinical trials examining treatments for Multiple Sclerosis and neurodegenerative disorders, including pioneering research in Frontotemporal Dementia and Parkinson's disease.

  • Multiple Sclerosis Therapies
  • Neurodegenerative Diseases
  • Brain Health Innovation

Research focuses on developing targeted treatments for various neurological conditions.

03 Infectious Diseases

Comprehensive vaccine development programs targeting Influenza, Cytomegalovirus, and meningococcal infections, with emphasis on preventive medicine.

  • Vaccine Development
  • Viral Infections
  • Immunization Studies

Studies aim to enhance vaccine efficacy and immune response across different age groups.

04 Oncology Research

Groundbreaking studies in cancer treatment, including research on bladder cancer and mantle cell lymphoma, exploring combination therapies and targeted treatments.

  • Cancer Immunotherapy
  • Targeted Therapies
  • Combination Treatments

Focus on developing innovative approaches to improve cancer treatment outcomes.

05 Autoimmune Conditions

Clinical investigations into Psoriatic Arthritis and inflammatory conditions, evaluating novel therapeutic approaches and treatment combinations.

  • Arthritis Treatment
  • Inflammatory Diseases
  • Immune System Disorders

Research aims to develop more effective treatments for chronic autoimmune conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.